CAR T-cell therapy in autoimmune diseases

Area of Science:

• Immunology and Medicine

Background:

• Autoimmune diseases like lupus, rheumatoid arthritis, and multiple sclerosis involve autoreactive B cells.
• Current treatments, including B-cell-depleting antibodies, often fail due to persistent autoreactive B cells in specific tissues.
• Chimeric antigen receptor (CAR) T-cell therapy has shown success in treating B-cell malignancies.

Purpose of the Study:

• To review evolving strategies for targeting autoreactive B cells using CAR T cells.
• To explore the potential of CAR T-cell therapy for treating autoimmune diseases.

Main Methods:

• Utilizing autologous T cells engineered with chimeric antigen receptors (CARs) targeting the CD19 antigen.
• Investigating the efficacy of CD19 CAR T cells in preclinical and clinical settings for autoimmune conditions.

Main Results:

• CD19 CAR T cells induce rapid and sustained depletion of circulating B cells.
• Successful clinical and serological remission observed in patients with refractory systemic lupus erythematosus and dermatomyositis.
• Demonstrated potential for targeting persistent autoreactive B cells in lymphatic organs and inflamed tissues.

Conclusions:

• CD19 CAR T-cell therapy represents a promising new modality for autoimmune diseases.
• This approach offers a targeted strategy against pathogenic autoreactive B cells.
• Further research into CAR T-cell strategies could revolutionize autoimmune disease treatment.